The state of the art of bispecific antibodies for treating human malignancies

The state of the art of bispecific antibodies for treating human malignancies

Abstract Bispecific antibodies (bsAb) that target two independent epitopes or antigens have been extensively explored in translational and clinical studies since they were first developed in the 1960s. Many bsAbs are being tested in clinical trials for treating a variety of diseases, mostly cancer....

Full description

Bibliographic Details
Main Authors: Shuhang Wang, Kun Chen, Qi Lei, Peiwen Ma, Andy Qingan Yuan, Yong Zhao, Youwei Jiang, Hong Fang, Shujun Xing, Yuan Fang, Ning Jiang, Huilei Miao, Minghui Zhang, Shujun Sun, Zicheng Yu, Wei Tao, Qi Zhu, Yingjie Nie, Ning Li
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:EMBO Molecular Medicine
Subjects:
bispecific antibodies (bsAb)
malignancies
single‐chain variable fragment (scFvs)
tumor associate antigen
tumor‐specific antigen
Online Access:https://doi.org/10.15252/emmm.202114291

Internet

https://doi.org/10.15252/emmm.202114291

Similar Items